Company intelligence / Profile preview

Alderaan Biotechnology

Paris, Île-de-France, France

Ownership: Private
Development stage: Preclinical

Overview

Alderaan Biotechnology is a French biotech company developing next-generation immunotherapies for cancer. Its lead program targets regulatory T cells using an IL2-sparing anti-CD25 monoclonal antibody (ALD2150), which has shown strong tumor growth inhibition and immune memory induction in preclinical models of gynecologic and breast cancers. The company is finalizing preclinical development with plans to enter clinical trials in 2024. A second program focuses on boosting NK cell cytotoxicity via the CD160-TM receptor.[4][6]

Therapeutic areas: Oncology
Modalities: Monoclonal antibodies (mAbs)Immunotherapies[4][6][9]
Industry: Biotech

Partnerships

Advent France Biotechnology (investor/board representation)[4]Medicxi (investor/board representation)[4]

Beyond the preview

Go deeper on Alderaan Biotechnology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Alderaan Biotechnology.

Explore the full profile